Repligen (RGEN)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$168.48-5.45%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
QuarterlyIQ Insights · RGEN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 57.1% |
| Our one-year growth estimate | diamond | 27.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 30.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 14 industry peers · Company calendar date is not available
RGEN — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-10-30
Unregistered Sales of Equity Securities. The Information set forth under
Why it matters: Adjusted operating margin rose to 15.9% in Q3. The full-year guide starts at 16%, while the GAAP result included a large impairment charge.
Watch forFY26 adjusted operating margin is at least 16.0%, within or above the 16.0%-16.3% guide.
Also watch forFY26 adjusted operating margin is below 16.0%, the bottom of the guide.
Why it matters: Repligen raised its revenue range after two quarters of strong organic growth. A result below the new range would break that trend.
Watch forFY26 reported revenue lands at or above $844 million, and organic growth is at least 12%.
Also watch forFY26 reported revenue falls below $844 million or organic growth falls below 12%.
Why it matters: The Seoul center adds training and customer support in a key biologics hub. The company has not yet shown how much APAC sales it brings.
Supportive ifA company update links the Seoul center to higher APAC sales or more customer orders.
Worry ifA company update reports flat or lower APAC sales. No new customer orders are tied to the center.
Why it matters: The note exchange changes the company’s debt and share count. The final terms and closing details can show the size of that change.
Watch forA filing confirms the $1.0 billion of 0.25% notes due 2031 were issued and states the final exchange terms.
Also watch forA filing reports that the note deal was changed, delayed, or not completed.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$172 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $488 loss on $10,000 · 4.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,028 loss on $10,000 · 40.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Repligen said BioLife adds repeat sales and cell therapy products. Reported savings show if the deal meets its cost goals.
Supportive ifA company update reports at least $20 million in BioLife synergies in year one.
Worry ifA company update reports less than $20 million in year-one synergies, or says the target was cut.